Richard Murray
Net Worth

Last updated:

What is Richard Murray net worth?

The estimated net worth of Dr. Richard Murray is at least $7,676,384 as of 4 Apr 2023. He has earned $1,482,364 from insider trading and has received compensation worth at least $6,194,020 in Jounce Therapeutics, Inc..

What is the salary of Richard Murray?

Dr. Richard Murray salary is $884,860 per year as Pres, Chief Executive Officer & Director in Jounce Therapeutics, Inc..

How old is Richard Murray?

Dr. Richard Murray is 66 years old, born in 1959.

What stocks does Richard Murray currently own?

As insider, Dr. Richard Murray owns shares in one company:

Company Title Shares Price per share Total value
Jounce Therapeutics, Inc. (JNCE) Pres, Chief Executive Officer & Director 188,779 $0 $0

What does Jounce Therapeutics, Inc. do?

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

JNCE logo
JNCE
Jounce Therapeutics, Inc.

Richard Murray insider trading

Jounce Therapeutics, Inc.

Dr. Richard Murray has made 15 insider trades between 2018-2023, according to the Form 4 filled with the SEC. Most recently he sold 39,228 units of JNCE stock worth $72,572 on 4 Apr 2023.

The largest trade he's ever made was exercising 40,000 units of JNCE stock on 23 Dec 2019. As of 4 Apr 2023 he still owns at least 188,779 units of JNCE stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 39,228 $1.85 $72,572
Sale
Common Stock 24,879 $1.12 $27,864
Sale
Common Stock 20,191 $1.1 $22,210
Sale
Common Stock 23,924 $6.65 $159,095
Sale
Common Stock 13,370 $7.3 $97,601
Sale
Common Stock 33,518 $0.48 $16,089
Option
Common Stock 33,518 N/A N/A
Option
Stock Option (Right to Buy) 33,518 N/A N/A
Option
Common Stock 16,482 N/A N/A
Option
Stock Option (Right to Buy) 16,482 N/A N/A
Sale
Common Stock 16,482 $12.04 $198,443
Option
Common Stock 40,000 $9.59 $383,600
Sale
Common Stock 40,000 $9.59 $383,600
Option
Stock Option (Right to Buy) 40,000 $9.59 $383,600
Option
Common Stock 30,000 N/A N/A
Option
Stock Option (Right to Buy) 30,000 N/A N/A
Sale
Common Stock 30,000 N/A N/A
Sale
Common Stock 11,816 N/A N/A
Sale
Common Stock 10,183 $6.76 $68,837
Sale
Common Stock 7,150 $7.78 $55,627
Option
Common Stock 40,000 $0.48 $19,200
Option
Stock Option (Right to Buy) 40,000 $0.48 $19,200
Sale
Common Stock 40,000 $0.48 $19,200
Option
Common Stock 32,000 $0.48 $15,360
Option
Stock Option (Right to Buy) 32,000 $0.48 $15,360
Sale
Common Stock 16,334 $0.48 $7,840
Option
Common Stock 16,334 $0.48 $7,840
Option
Stock Option (Right to Buy) 16,334 $0.48 $7,840
Option
Stock Option (Right to Buy) 16,334 $0.48 $7,840
Option
Common Stock 16,334 $0.48 $7,840
Sale
Common Stock 16,334 $21.64 $353,386

Jounce Therapeutics key executives

Jounce Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. Richard Murray (66) Pres, Chief Executive Officer & Director
  • Mr. Hugh M. Cole (60) Chief Bus. Officer & Head of Corporation Devel.
  • Ms. Kimberlee Cobleigh Drapkin CPA, CPA (57) Chief Financial Officer & Treasurer